Abstract | BACKGROUND/OBJECTIVES: METHODS: Secondary analysis of a prospective, interventional study including 100 patients with ADHF. Fifty patients were non-randomly assigned to spironolactone 100 mg/day plus standard ADHF therapy (intervention group) or standard ADHF therapy alone (control group). RESULTS: Patients in control group were older, had higher creatinine and urea levels, and had higher proportion of microalbuminuria (all, P < 0.05). Paired comparison of baseline and day 3 log albuminuria within each group, showed a more pronounced decrease in the intervention group (1.79 ± 0.75 to 1.59 ± 0.67, P = 0.003 vs 1.89 ± 0.70 to 1.79 ± 0.74, P = 0.096). In addition, the proportion of patients with normoalbuminuria increased from baseline to day 3 in spironolactone group (20 (40%) to 27 (54%), P < 001), accordingly the number of patients in the micro and macroalbuminuria groups was reduced. Day 1 albuminuria was positively correlated with day 1 N-terminal pro- brain natriuretic peptide (0.260 [0.105-0.758], P = 0.009). CONCLUSIONS: High-dose spironolactone added to standard ADHF therapy is likely to induce a more pronounced albuminuria decrease and a significant reduction in the proportion of micro and macroalbuminuria.
|
Authors | João Pedro Ferreira, Mário Santos, Sofia Almeida, Irene Marques, Paulo Bettencourt, Henrique Carvalho |
Journal | Nephrology (Carlton, Vic.)
(Nephrology (Carlton))
Vol. 19
Issue 3
Pg. 149-56
(Mar 2014)
ISSN: 1440-1797 [Electronic] Australia |
PMID | 24533733
(Publication Type: Clinical Trial, Comparative Study, Journal Article)
|
Copyright | © 2013 Asian Pacific Society of Nephrology. |
Chemical References |
- Biomarkers
- Spironolactone
|
Topics |
- Aged
- Aged, 80 and over
- Albuminuria
(drug therapy)
- Biomarkers
- Female
- Heart Failure
(diagnosis, drug therapy, urine)
- Humans
- Male
- Prospective Studies
- Spironolactone
(therapeutic use)
|